Faro, which develops data models and AI tools to speed up clinical trials, raised a $37.3M Series B co-led by Merck Global Health Innovation Fund and S32
What's the deal? Faro has raised a $37 million Series B round to develop AI tools aimed at speeding up clinical trials.
Context & Ripple Effects
Faro's 2023 Series A funded cloud software designed to provide real-time trial insights; this round gives that earlier platform a larger base for expanding from trial insights into AI-enabled development tools.
The financing lands in a clinical-development software market already attracting large rounds: Barcelona-based Biorce raised $52.5 million for an AI service aimed at faster trials, while Reify Health had previously raised $220 million for cloud trial-research tools. Merck Global Health Innovation Fund's co-lead makes Faro's progress relevant to both software investors and pharmaceutical-development backers.
First-order effects
- Faro gains $37.3 million to develop AI tools intended to shorten clinical-trial work, extending the company beyond the real-time insight software it described in 2023.
- Merck Global Health Innovation Fund and S32 become the round's co-leads, aligning Faro with investors focused on healthcare innovation and technology scaling.
Second-order effects
- Faro and Biorce are competing for clinical-development teams seeking faster trials, raising the premium on evidence that AI tools improve operational timelines rather than simply add analytics features.
- Established cloud trial-software providers, including Reify Health, face a more explicit market expectation that trial-data platforms support AI-driven workflows.
Third-order effects
- If AI tools can be embedded in trial operations rather than used only for reporting, clinical-development software may shift from systems of record toward systems that structure and accelerate work across the trial lifecycle.
- Pharma-linked investors may become more consequential in clinical AI funding because vendors need both capital and a credible route into regulated development workflows.
The trend: Clinical-trial software is moving from cloud-based visibility tools toward AI systems designed to accelerate operational decisions and workflows.